India's AMR Emergency: Where Drought, Over-the-Counter Antibiotics, and Industrial Pollution Converge

India accounts for approximately 20 percent of global antibiotic consumption. It carries some of the highest antimicrobial resistance rates documented anywhere. Its ICMR surveillance network reports carbapenem resistance exceeding 50 percent in Klebsiella pneumoniae isolates at some tertiary hospitals. At the same time, drought conditions are expanding across Rajasthan, Maharashtra, Karnataka, and parts of Tamil Nadu. The Newman et al. 2026 finding that drought concentrates natural soil antibiotics and selects for resistant bacteria adds a variable to India's AMR crisis that no current policy framework addresses.

This is an inventory of where the situation stands and what the compound risk looks like.

The Resistance Numbers

India's AMR burden is among the world's highest by multiple measures. The Indian Council of Medical Research operates the AMR surveillance network through approximately 30 sentinel sites across the country. Data from this network, published in the ICMR annual reports, shows resistance rates that exceed global averages for most priority pathogens.

Carbapenem-resistant Klebsiella pneumoniae, a pathogen classified as critical priority by WHO, shows resistance rates between 40 and 70 percent at Indian tertiary care hospitals depending on the site and year. For context, European averages range from 5 to 25 percent for the same pathogen. Extended-spectrum beta-lactamase producing E. coli, which renders common first-line antibiotics ineffective, is reported at rates above 70 percent in many Indian hospitals. Methicillin-resistant Staphylococcus aureus rates hover between 25 and 50 percent across ICMR sites.

These numbers come from tertiary hospitals with laboratory capacity to identify resistance. The majority of India's 1.4 billion people access healthcare at primary health centres and district hospitals that lack microbiology laboratories. Resistance rates in these settings are unknown. Clinical suspicion and prior experience guide antibiotic selection rather than culture and sensitivity testing.

The Lancet 2022 study estimated India's per-capita AMR-associated death rate as among the highest in South Asia. The true number is almost certainly higher than the estimate, given the surveillance gaps.

The Consumption Pattern

India consumed an estimated 6.5 billion defined daily doses of antibiotics in 2015, according to data published by the Center for Disease Dynamics, Economics and Policy. Per-capita consumption increased by approximately 65 percent between 2000 and 2015, one of the steepest increases globally.

Several factors drive this consumption. Antibiotics remain available over the counter at pharmacies across much of India despite regulatory efforts. The Central Drugs Standard Control Organisation, India's drug regulatory body under the Directorate General of Health Services, has placed certain antibiotics on Schedule H1, requiring a prescription. Enforcement varies widely. A 2019 study published in PLOS Medicine found that approximately 50 percent of antibiotic sales in parts of India occurred without a prescription.

Self-medication is common, particularly in rural areas where access to qualified doctors is limited. Patients frequently purchase incomplete courses at doses determined by affordability rather than clinical need. Subtherapeutic dosing is a direct driver of resistance: bacteria exposed to antibiotics at concentrations too low to kill them develop resistance instead.

The private healthcare sector, which provides approximately 70 percent of outpatient care in India, operates with limited regulatory oversight of prescribing practices. Antibiotic prescribing rates in Indian hospitals exceed WHO recommendations across most categories. The AWaRe framework, which recommends that at least 60 percent of antibiotic prescriptions should be from the Access group, is not met in the majority of Indian healthcare settings.

The Drought Map

India's relationship with drought has intensified over the past two decades. The India Meteorological Department reported that between 2015 and 2024, drought conditions affected an expanding footprint across western Rajasthan, the Vidarbha and Marathwada regions of Maharashtra, northern Karnataka, and the Rayalaseema region of Andhra Pradesh. Parts of Tamil Nadu face periodic severe drought linked to monsoon variability.

These drought-affected regions overlap substantially with areas of high antibiotic consumption and limited healthcare infrastructure. Rajasthan's arid western districts, Maharashtra's cotton belt in Vidarbha, and Karnataka's northern plateau combine water stress, agricultural dependence, and constrained access to hospital-based healthcare. In these areas, soil dries for extended periods during failed monsoons.

The Newman finding is directly relevant here. Drying soils concentrate natural antibiotics produced by soil bacteria. Resistant bacteria proliferate under this selection pressure. When dust carries these organisms, when groundwater percolates through resistant soil communities, when crops grow in soil dominated by resistant microorganisms, the environmental resistance pool feeds into the human population.

No Indian study has yet measured the specific contribution of soil-derived resistant bacteria to clinical infections in drought-affected regions. The mechanism identified by Newman et al. predicts that this contribution exists and grows with aridification. India's expanding drought footprint makes quantifying this contribution an urgent research priority.

The Pharmaceutical Pollution Factor

India manufactures a significant share of the world's generic antibiotics. Hyderabad's Patancheru-Bollaram industrial area and surrounding zones host dozens of pharmaceutical manufacturing facilities, including major antibiotic producers. Environmental monitoring studies have found antibiotic concentrations in effluent from these facilities that exceed therapeutic levels.

Research published by the Changing Markets Foundation and Nordea Asset Management documented ciprofloxacin concentrations in wastewater near Hyderabad manufacturing facilities at levels hundreds of times higher than what would be expected in the bloodstream of a patient taking the drug. These concentrations create extreme selection pressure for resistant bacteria in local waterways, sediment, and soil.

This pharmaceutical pollution constitutes a third driver of environmental resistance, distinct from both clinical antibiotic use and the drought mechanism. In regions where manufacturing effluent reaches agricultural land and water sources, the resistance pressure on soil bacteria comes from three directions simultaneously: natural antibiotics concentrated by drought, manufactured antibiotics discharged in wastewater, and clinical antibiotics excreted by treated patients and livestock reaching the environment.

The Telangana State Pollution Control Board has issued guidelines for pharmaceutical effluent treatment. Compliance monitoring remains inconsistent. The problem extends beyond Hyderabad to pharmaceutical manufacturing zones in Visakhapatnam, Baddi in Himachal Pradesh, and Tarapur in Maharashtra.

The National Action Plan: Policy vs. Implementation

India published its National Action Plan on Antimicrobial Resistance in 2017, aligning with the WHO Global Action Plan timeline. The plan established objectives across six strategic priority areas: improving awareness, strengthening surveillance, reducing infection, optimizing antibiotic use, promoting investment in AMR research, and strengthening India's engagement in international collaboration.

Implementation has been uneven. The ICMR surveillance network has expanded from its initial pilot sites but still covers a fraction of India's healthcare facilities. The Red Line campaign, launched in 2016 to mark prescription-only antibiotics with a red stripe on packaging, increased public awareness but did not substantially reduce over-the-counter sales according to follow-up assessments.

The Food Safety and Standards Authority of India has set maximum residue limits for antibiotics in food products, targeting agricultural antibiotic use. Enforcement in a country with approximately 150 million farming households and fragmented supply chains is a challenge of a different order than in European countries with consolidated agricultural sectors.

What the National Action Plan does not address is environmental resistance. The plan focuses on rational prescribing, infection control, and surveillance of clinical resistance. It does not account for drought-driven resistance in soil, pharmaceutical effluent creating resistant environments, or the expanding arid zones that the Newman finding identifies as accelerators of environmental resistance.

Assessment: India's National Action Plan represents a necessary step. It is built on the same clinical-and-agricultural framework as the WHO Global Action Plan. In a country where clinical and agricultural antibiotic misuse are acute problems, this focus is understandable. It is also incomplete. India's compound exposure to environmental resistance drivers, from drought, manufacturing pollution, and inadequate wastewater treatment, creates a dimension that the current policy framework does not address.

The Compound Risk

India's AMR crisis is frequently described as a problem of antibiotic misuse. This is accurate but partial. The country faces a convergence of at least four resistance drivers operating simultaneously.

Clinical misuse drives resistance through over-the-counter access, incomplete courses, and overprescribing. Agricultural use of antibiotics as growth promoters in poultry and livestock adds to the selective pressure. Pharmaceutical manufacturing pollution creates environmental hotspots where resistance genes proliferate. Climate-driven drought concentrates natural soil antibiotics, selecting for resistant bacteria through a mechanism entirely independent of human antibiotic use.

These four drivers do not simply add up. They interact. Resistant bacteria selected by drought in soil acquire additional resistance genes from pharmaceutical effluent in water. These multi-resistant organisms reach patients who are then treated with antibiotics prescribed empirically because diagnostic capacity is lacking, completing a cycle that no single intervention can break.

The ICMR has called for expanded surveillance. The WHO has recommended a One Health approach. The Newman finding suggests that India's AMR trajectory cannot be projected from clinical resistance data alone, because a significant and growing portion of the resistance pressure comes from environmental processes that clinical surveillance does not capture.

India's combination of high population density, expanding drought, massive antibiotic consumption, pharmaceutical manufacturing infrastructure, and limited diagnostic capacity makes it the country where the climate-AMR nexus will be tested first and most acutely. The policy response has not yet caught up with the complexity of the problem.